Trial Profile

Phase2 trial of oxaliplatin, irinotecan and S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer (HGCSG1803)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
Indications Pancreatic cancer
Focus Therapeutic Use

20 Jan 2024 Primary endpoint (objective response rate (ORR) has been met according to Results presented at the 2024 Gastrointestinal Cancers Symposium.
20 Jan 2024 Results (n=39) assessing safety and efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment presented at the 2024 Gastrointestinal Cancers Symposium
01 Jul 2023 Results assessing To evaluate Efficacy and safety of OX-IRIS, HGCSG1803 study has conductedas a multicenter, non-randomized, single arm, prospective, phase II study in Japan presented at the 25th World Congress on Gastrointestinal Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com